bromley wrote:The Sunday Times says that Tysabri might get FDA approval this week.
Yep, right on the predicted schedule!
Sorry to spoil you Sunday lunch HarryZ
Perhaps you could turn your attention to Rituxan or Dacluzimab.
Nah....too much fun following Tysabri
The re-approval starts a new chapter with this drug and there are likely going to be many pages to read in this saga!
The article says that Tysabri will be $23,000 a year. About as much as Harry takes each month from the dividends from his Biogen shares.
Good luck if anyone thinks that Tysabri will cost them (I mean their insurance company) only $23,000 a year! That covers the wholesale cost of the drug and not the associated infusion costs and other mark-ups. When Tysabri was available to the general public in January and February of 2005, users were reporting a total cost for the drug and infusion of anywhere from $ 2300 all the way up to $5300!! At 13 infusions a year, do the math.....staggering!
Ever notice that most of the announcements about Tysabri come from the financial world...kind of indicates where the importance sits with this and most big pharma medications.
In the meantime Ian, I'll go and count my last month's dividends from Biogen...right!!